LOS ANGELES, CA / ACCESS Newswire / February 12, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...

After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...

AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics, which spun out of Pfizer ...

The carve-out acquisition will allow Bain to capitalize on the “promising signs for growth” in the Japanese life sciences ...

Despite the death of its golden goose, AbbVie expects to achieve high single-digit compound annual sales growth to the end of ...

North Chicago-based pharmaceutical giant AbbVie acquired the drug, called emraclidine, in an $8.7 billion acquisition of Cerevel Therapeutics last year. At the time, industry analysts predicted ...

Sometimes they don't, as AbbVie is finding out the hard way. The company's $8.7 billion buyout of Cerevel Therapeutics now looks like a waste of money after the leading asset it got from that ...

AbbVie’s market capitalisation grew by 14.8% in 2024, fueled by its acquisitions of ImmunoGen in February and Cerevel Therapeutics in August, totalling $19bn. These strategic moves bolstered AbbVie’s ...

The drug, picked up in AbbVie's $8.7 billion acquisition of Cerevel Therapeutics, failed to ease symptoms like hallucinations and delusions, leading the company to book a staggering $3.5 billion ...

According to DelveInsight’s epidemiology model, the total diagnosed prevalent cases of Parkinson’s disease were approximately ...